For example, with respect to factor VIII (FVIII) replacement therapy in hemophilia A, Antihemophilic Factor (Recombinant), PEGylated (rurioctocog alfa pegol, BAX 855, SHP660; ADYNOVI®/ADYNOVATE®, Shire, Lexington, MA, USA) has a half-life that is 1.4–1.5 fold longer [6,11] than Antihemophilic Factor (Recombinant) (ADVATE®, Shire Lexington, MA, USA), allowing for two doses per week rather than three for prophylaxis [6,11,12]. This evidence concerns the gene F8 and hemophilia A.